Novacyt (NCYT)

325.50
+2.50(+0.77%)
  • Volume:
    245,867
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    321.30 - 329.90

NCYT Overview

Prev. Close
323
Day's Range
321.3-329.9
Revenue
-
Open
325.3
52 wk Range
275-1,276
EPS
-
Volume
245,867
Market Cap
229.89M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
569,325
P/E Ratio
-
Beta
-
1-Year Change
6.72%
Shares Outstanding
70,613,705
Next Earnings Date
17 Aug 2021
What is your sentiment on Novacyt S.A?
or
Market is currently closed. Voting is open during market hours.

Novacyt S.A News

  • Novacyt S.A. reports FY results
    • BySeeking Alpha-

    Novacyt S.A. (NVYTF): FY GAAP EPS of£1.94.Revenue of£277.2M (+2310.4% Y/Y)Gross margin increased to 76.3% in 2020 from 64.0% in 2019.EBITDA increased to £176.1M in...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellNeutral
Technical IndicatorsNeutralStrong SellBuyStrong SellStrong Sell
SummarySellStrong SellNeutralStrong SellSell

Novacyt S.A Company Profile

Novacyt S.A Company Profile

Employees
174
Market
France

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Lab21 Products, IT-IS International, and Primerdesign segments. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The Primerdesign segment designs, manufactures, and markets molecular ‘real-time’ qPCR testing devices and reagents in the areas of infectious diseases. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company’s diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves public hospitals, central laboratories, private testing, and mobile laboratories. Novacyt S.A. was incorporated in 2006 and is headquartered in Camberley, the United Kingdom.

Read More
  • We are close to the bottom
    0
    • Guys just a hegde fund got out. nothing to worry about it you hold with time horizon 1-3 yrs
      5
      • if smart guys are getting out, then that should be something to worry about...
        2
      • If all hedge funds were managed by "smart guys", then there wouldn't be a situation like the one with Game Stop stocks.
        0
      • Also, HFs are probably looking at this short-term, where they are clearly not seeing any rise and profit, but only risk for some losses. Them stepping out of the trade doesn't necessarily need to mean anything. I believe this company will eventually come to some agreement with UK and continue the production as planned. Then, the price will start to rise again, but it is unknown if and when that will happen, that's just me hoping for it.
        0
    • I say better to share what u know instead of clicking thumbs down, even u disagree say why, at the end of the day we all here to make money.
      2
      • i am guessing the reason the SP is coming down is cause there might be more competition now and the value of the company will not be worth as high as it was in 2020. i will be if anyone knows anything who can add more.
        2
        • it lost 60% because they miss to renew uk’s hns contract then two weeks after in two sessions almost 40% with encouraging news from framework contract it will be back to 8 eur within a couple weeks... it is a good cheap company
          1
          • Guys - the share will increase to 8€ without 2 weeks. No stress !
            4
            • profit taking.
              2
              • Those who listened to me would have been 40% in green
                1
                • WOW!!!!
                  1
                  • Keep buying
                    1
                    • this gone pass 500 soon.
                      1
                      • Good call.
                        1
                    • Beautiful bounce
                      1
                      • Looks poised to bounce even more.
                        1
                      • This will go back above 700. Be patient folks
                        1
                    • Already sitting on a 10% profit for the lot I bought at 395. Happy days
                      6
                      • Guys, we are not talking about BTC here. This stock has intrinsic value. It is sitting on a huge cash pile. It will bounce back to around 600 to 700 level in a couple of weeks.
                        2
                      • i hope so, my avg is 700 :( sitting on a big virtual loss.
                        0
                      • I doubt it bounces back all the eay if the contract they lost was half of their turnover. if they make up some of that i say it maybe goes to 500level not back to where it was
                        1
                    • Not the news we are hoped for... 😣 Total let down.
                      3
                      • All*..
                        0
                      • tbf should go to 250-300p at cash levels now.
                        3
                      • Patience my friend, that's the name of the game. At first I wasn't aware of this company, but then I read in some news about this issue with the contract and how it affected its price to drop down. Then I read a little bit about the company and I have strong belief that they will come to some agreement and will continue working in the usual way like they did, which will be followed by the price surge. Same thing happened with AstraZeneca when they first declared their vaccine to be "unsafe" - price dropped and soon afterwards it recovered.
                        1
                    • Last chance to buy at this bargain level. TP 940p
                      5
                      • TP is based on the projected future cash flow. This company has zero debt and very cash generative! Don't be put off by the price volatility... This is a norm in Aim.
                        2
                      • ROFL
                        0
                    • WHEN YOU PROFIT FROM A GHASTLY PANDEMIC THIS IS WHAT YOU GET...
                      4
                      • :-( lesson learned
                        0
                    • https://www.businesswire.com/news/home/20210409005201/en/Novacyt-S.A.-Novacyt-the-Company-or-the-Group-Trading-Update
                      3
                      • Don't forget that their CEO bought at 817p for amount of 500k£ back in Nov. I think the drop is overdone.
                        3
                    • Rip
                      3
                      • Wonder if this is now going to 370
                        3
                        • Buy buy buy 🚀
                          4
                          • Ignore broker targets, its of little relevance in the UK. But I think this may have a little further to go yet considering the relentless falls...
                            3
                            • Broker target 1365. https://mobile.twitter.com/Kat_Hassard/status/1364511710225252356
                              3
                              • Hopefully that was rock bottom.. 📈
                                2
                                • got the vaccine today.  looking optimistic to the future now in UK.
                                  7
                                  • Seems so undervalued right now, PE is around 2 , also we are making 1m profit / day. Bargain ???
                                    2
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.